title: Drug susceptibility of Mycobacterium tuberculosis in patients with AIDS at a tertiary care hospital in northern India.
abstract: The study was done to determine the anti-tuberculosis drug resistance patterns of Mycobacterium tuberculosis (MTB) in AIDS patients. Fifty antiretroviral drug naïve new AIDS patients with clinical evidence of pulmonary tuberculosis and no previous history of tuberculosis were recruited. Baseline CD4 counts and plasma viral loads (PVL) were measured by flow cytometry and RT-PCR, respectively. Sputum samples were obtained from each patient and subjected to Ziehl-Neelsen staining and cultured on Lowenstein-Jensen medium and using the BACTEC 460 system (B460). Antimicrobial susceptibilities were tested in all isolates using the B460 gystem. The occurrence of MTB was found to be more common with a PVL>4 log10 copies/ml (odds ratio: 4.6). Of 15 MTB isolates, 8 (53.3%) had single drug resistance, 4 (26.7%) had multidrug resistance (MDR) and 1 (6.7%) had resistance to three drugs (non-MDR). Two isolates (13.3%) were sensitive to all the four drugs. Resistance to first line anti-tuberculosis drugs was found to be higher among AIDS patients with MTB.
authors.affiliation: Department of Microbiology, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India. drhitender@gmail.com
authors.forename: H
authors.initials: H
authors.lastname: Gautam
authors.forename: P
authors.initials: P
authors.lastname: Bhalla
authors.forename: G
authors.initials: G
authors.lastname: Vidyanidhi
authors.forename: S
authors.initials: S
authors.lastname: Saini
authors.forename: H
authors.initials: H
authors.lastname: Jha
authors.forename: C P
authors.initials: CP
authors.lastname: Baveja
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D024901:Drug Resistance, Multiple, Bacterial; D004977:Ethambutol / Q000494:pharmacology; D005260:Female; D006801:Humans; D007194:India / Q000453:epidemiology; D007538:Isoniazid / Q000494:pharmacology; D008297:Male; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012293:Rifampin / Q000494:pharmacology; D013183:Sputum / Q000382:microbiology; D013307:Streptomycin / Q000494:pharmacology; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D019562:Viral Load
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin